Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The RVPH news feed highlights the company’s progress in advancing its pipeline, particularly its lead candidate brilaroxazine (RP5063), which is being developed for schizophrenia and explored for additional indications such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
News updates commonly cover clinical trial milestones, including data from the Phase 3 RECOVER program in schizophrenia and its 1-year open-label extension. Reviva has reported broad-spectrum efficacy across major symptom domains, reductions in proinflammatory cytokines, and long-term safety and tolerability data for brilaroxazine. The company also releases information on biomarker research, such as vocal biomarker analyses that use speech latency to characterize negative symptoms and enrich antipsychotic clinical trials.
Regulatory and corporate developments are another key theme in RVPH news. Investors can follow announcements related to FDA interactions, including pre-New Drug Application (pre-NDA) feedback recommending a second Phase 3 trial in schizophrenia, as well as plans for the RECOVER-2 registrational study, subject to financing. Updates on Orphan Drug Designation for PAH and IPF, European patent grants for pulmonary fibrosis, and broader intellectual property strategy are also featured.
In addition, the news flow includes participation in scientific meetings, investor conferences, and key opinion leader events, where Reviva presents clinical and mechanistic data on brilaroxazine. For market participants tracking RVPH stock, this page consolidates company-issued press releases on clinical data, regulatory guidance, financing transactions, and strategic presentations in one place.
Reviva (NASDAQ: RVPH) reported full-year 2025 results and business updates on March 30, 2026. The company disclosed a net loss of $19.9M for 2025 and cash of $14.4M at year-end. Reviva received FDA written recommendations calling for a second Phase 3 trial and plans to initiate RECOVER-2 in mid-2026. The company completed NDA-enabling studies, cGMP registration manufacturing, and raised gross proceeds from public offerings in 2025–2026.
Reviva Pharmaceuticals (NASDAQ: RVPH) closed a public offering on March 20, 2026, raising approximately $10.0 million gross by selling 6,666,667 common shares with accompanying Series G and Series H warrants at a combined price of $1.50 per share and warrant package.
The Series G and H warrants have a $1.50 exercise price; G warrants expire in five years and H warrants expire in 12 months. The company reported approximately $23 million cash post-close, which it believes funds operations into Q1 2027, and intends to use proceeds to fund R&D including the RECOVER-2 Phase 3 trial for brilaroxazine, plus working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH) priced a public offering to raise approximately $10.0 million by selling 6,666,667 common shares with attached Series G and Series H warrants at a combined price of $1.50 per share and warrant.
The Series G and Series H warrants have an exercise price of $1.50; G warrants expire five years and H warrants expire 12 months from issuance. Closing is expected on or about March 20, 2026. The company intends to use proceeds to fund R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and general corporate purposes.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced on March 18, 2026 that it intends to conduct a public offering of its common stock (or equivalents) and warrants. The offering is subject to market conditions and may not be completed.
The company said it plans to use net proceeds and existing cash to fund research and development, including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital. A.G.P./Alliance Global Partners is the sole placement agent. The securities will be offered under an effective Form S-3 shelf registration declared effective February 13, 2024.
Reviva (NASDAQ: RVPH) announced publication on Jan 8, 2026 in Biological Psychiatry reporting vocal biomarker findings from the RECOVER Phase 3 trial of brilaroxazine for schizophrenia. The paper presents speech latency as an interpretable vocal biomarker that classifies moderate-to-severe vs low negative symptoms, correlates with clinician-assessed efficacy, and identifies a subgroup (VBM-positive) with stronger, faster responses to brilaroxazine. The authors state speech latency can be measured from psychiatric interviews across languages and may be used to enrich trials, reduce sample-size needs, and lower trial costs and placebo effects.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will present a corporate presentation at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026 in San Francisco.
Presentation details: Date: January 11, 2026; Time: 1:20 PM PT; Presenter: Laxminarayan Bhat, Ph.D.; Location: Marines’ Memorial Club, San Francisco, CA.
Reviva (NASDAQ: RVPH) announced a regulatory update on Dec 23, 2025 following a pre-NDA meeting with the FDA about brilaroxazine for schizophrenia. The FDA provided written feedback recommending a second Phase 3 trial to generate additional efficacy and safety data prior to an NDA submission. Reviva plans to initiate the RECOVER-2 registrational trial in H1 2026, subject to sufficient financing. The company said its current data package shows broad-spectrum efficacy across symptom domains in 790 subjects, a generally well-tolerated safety profile in over 900 subjects, favorable adherence, and up to one-year safety data for once-daily oral dosing. FDA also gave guidance on data analysis, animal PK, abuse potential, and renal/hepatic impairment studies.
Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q3 2025 results and recent program milestones on November 13, 2025. Key clinical and corporate updates include a planned pre-NDA meeting with FDA in Q4 2025 and a targeted NDA submission in Q2 2026 for brilaroxazine in schizophrenia. The company reported positive 1-year open-label extension (OLE) data (N=446) showing sustained PANSS and functional improvements and generally favorable safety findings.
Other highlights: European patent granted for brilaroxazine in pulmonary fibrosis, completed a public equity offering raising $9.0 million gross, reported a Q3 net loss of $4.0 million, and held $13.2 million cash as of September 30, 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) will present new data on the anti-inflammatory effects of brilaroxazine at Neuroscience 2025 in San Diego.
The late-breaker poster (Session A.10, LBP010) on Nov 15, 2025, 1:00–5:00 PM PT covers RECOVER Phase 3 double-blind results in acute schizophrenia and 12-month open-label extension data in clinically stable patients, focusing on BDNF and inflammatory cytokines. Abstracts and poster details are available on the Neuroscience 2025 website.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that European Patent 3749324 was granted by the EPO on Nov 10, 2025, covering use of brilaroxazine to treat pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF).
The patent adds to existing protection in key markets including the United States, China, and Japan. Brilaroxazine is described as having a novel mechanism that targets disrupted serotonin signaling implicated in pulmonary fibrosis. The drug has received Orphan Drug Designation from the U.S. FDA for IPF. Management said the asset is late-stage and has been well-tolerated across large patient populations, supporting plans to expand clinical development from schizophrenia into additional indications.